AR034493A1 - Combinacion de principios activos para el tratamiento medico de toxicomanias. - Google Patents

Combinacion de principios activos para el tratamiento medico de toxicomanias.

Info

Publication number
AR034493A1
AR034493A1 ARP020102244A ARP020102244A AR034493A1 AR 034493 A1 AR034493 A1 AR 034493A1 AR P020102244 A ARP020102244 A AR P020102244A AR P020102244 A ARP020102244 A AR P020102244A AR 034493 A1 AR034493 A1 AR 034493A1
Authority
AR
Argentina
Prior art keywords
combination
medical treatment
toxicomans
active principles
antiexciting
Prior art date
Application number
ARP020102244A
Other languages
English (en)
Spanish (es)
Inventor
Klaus Opitz
Joachim Moormann
Hermann Mucke
Original Assignee
Hf Arzneimittelforsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hf Arzneimittelforsch Gmbh filed Critical Hf Arzneimittelforsch Gmbh
Publication of AR034493A1 publication Critical patent/AR034493A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
ARP020102244A 2001-06-18 2002-06-14 Combinacion de principios activos para el tratamiento medico de toxicomanias. AR034493A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10129265A DE10129265A1 (de) 2001-06-18 2001-06-18 Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie

Publications (1)

Publication Number Publication Date
AR034493A1 true AR034493A1 (es) 2004-02-25

Family

ID=7688529

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102244A AR034493A1 (es) 2001-06-18 2002-06-14 Combinacion de principios activos para el tratamiento medico de toxicomanias.

Country Status (27)

Country Link
US (1) US20040192683A1 (https=)
EP (1) EP1397138B1 (https=)
JP (1) JP2005500298A (https=)
KR (1) KR20040010744A (https=)
CN (1) CN1527711A (https=)
AR (1) AR034493A1 (https=)
AT (1) ATE286397T1 (https=)
AU (1) AU2002323873B2 (https=)
BR (1) BR0211008A (https=)
CA (1) CA2450787C (https=)
CZ (1) CZ299951B6 (https=)
DE (2) DE10129265A1 (https=)
EA (1) EA006647B1 (https=)
ES (1) ES2236551T3 (https=)
HU (1) HUP0400865A3 (https=)
IL (2) IL159345A0 (https=)
MX (1) MXPA03011825A (https=)
MY (1) MY129726A (https=)
NO (1) NO20035458D0 (https=)
NZ (1) NZ529944A (https=)
PL (1) PL367207A1 (https=)
PT (1) PT1397138E (https=)
SK (1) SK287180B6 (https=)
TW (1) TWI325320B (https=)
UA (1) UA76753C2 (https=)
WO (1) WO2002102388A2 (https=)
ZA (1) ZA200309232B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
DE10318714B4 (de) * 2003-04-25 2006-03-23 Hf Arzneimittelforschung Gmbh Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
DE102004048927A1 (de) * 2004-10-06 2006-04-20 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Kombination enthaltend Desoxypeganin und Cyp2D6 Inhibitoren
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Cns関連疾患の治療のための方法及び組成物
WO2006124585A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug system for the delivery of galantamine
CN102408548B (zh) 2005-09-01 2013-05-15 布勒公司 聚对苯二甲酸乙二醇酯的制造方法
EP1937226A2 (en) * 2005-09-23 2008-07-02 Alza Corporation Transdermal galantamine delivery system
CA2781830C (en) 2009-02-12 2018-03-27 Indiana University Research & Technology Corporation Materials and methods for treating developmental disorders including comorbid and idiopathic autism
MX365650B (es) 2009-12-02 2019-06-10 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
MX346203B (es) * 2010-09-28 2017-03-09 Depomed Inc Formas de dosificacion retentivas gastricas para liberacion prolongada de acamprosato en el tracto gastrointestinal superior.
SMT202500474T1 (it) * 2010-12-03 2026-01-12 Nalpropion Pharmaceuticals Llc Aumento della biodisponibilità farmacologica nella terapia con naltrexone
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
TWI678202B (zh) * 2016-12-14 2019-12-01 陸汝斌 組合物用於製備治療酒癮或酒精濫用之藥物的用途
CA3072764A1 (en) 2017-08-24 2019-02-28 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use
BG67408B1 (bg) * 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
DE3843239C1 (https=) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
EP0424179A3 (en) * 1989-10-20 1991-12-27 John William Olney Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
WO1996012692A1 (de) * 1994-10-21 1996-05-02 Waldheim Pharmazeutika Gesellschaft M.B.H. VERFAHREN ZUM HERSTELLEN VON DERIVATEN DES 4a,5,9,10,11,12,-HEXAHYDRO-6H-BENZOFURO[3a,3,2-ef][2]BENZAZEPINS
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
WO1999054280A1 (en) * 1998-04-17 1999-10-28 Kenneth Curry Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit

Also Published As

Publication number Publication date
PL367207A1 (en) 2005-02-21
CA2450787A1 (en) 2002-12-27
SK15652003A3 (sk) 2004-04-06
ATE286397T1 (de) 2005-01-15
SK287180B6 (sk) 2010-02-08
IL159345A (en) 2009-02-11
CA2450787C (en) 2009-06-02
IL159345A0 (en) 2004-06-01
DE10129265A1 (de) 2003-01-02
TWI325320B (en) 2010-06-01
MXPA03011825A (es) 2005-03-07
EP1397138B1 (de) 2005-01-05
HK1063292A1 (en) 2004-12-24
HUP0400865A2 (hu) 2004-07-28
WO2002102388A2 (de) 2002-12-27
CZ20033390A3 (en) 2004-03-17
KR20040010744A (ko) 2004-01-31
EP1397138A2 (de) 2004-03-17
ES2236551T3 (es) 2005-07-16
ZA200309232B (en) 2004-07-21
US20040192683A1 (en) 2004-09-30
CN1527711A (zh) 2004-09-08
DE50201958D1 (de) 2005-02-10
JP2005500298A (ja) 2005-01-06
EA006647B1 (ru) 2006-02-24
HUP0400865A3 (en) 2011-03-28
BR0211008A (pt) 2004-10-26
WO2002102388A3 (de) 2003-09-18
NZ529944A (en) 2007-02-23
EA200400041A1 (ru) 2004-04-29
AU2002323873B2 (en) 2006-11-16
PT1397138E (pt) 2005-04-29
CZ299951B6 (cs) 2009-01-07
UA76753C2 (uk) 2006-09-15
NO20035458D0 (no) 2003-12-08
MY129726A (en) 2007-04-30

Similar Documents

Publication Publication Date Title
AR034493A1 (es) Combinacion de principios activos para el tratamiento medico de toxicomanias.
ATE450252T1 (de) Arzneimittel-mikroteilchen
UY27940A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a
DE60239707D1 (de) Antimikrobielle kationische peptide und diese enthaltende formulierungen
AR032293A1 (es) Estuche farmaceutico
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
BR0207760A (pt) Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição
DE60214173D1 (de) Negativ geladenes amphiphiles blockcopolymer als arzneistoffträger und komplex davon mit postitiv geladenem arzneistoff
DK1345595T3 (da) Ionstyrke-uafhængig farmaceutisk formulering med depotfrigivelse
DE60220796D1 (de) Positiv geladenes amphiphiles blockcopolymer als arzneistoffträger und komplex davon mit negativ geladenem arzneistoff
BR0108499A (pt) Agente terapêutico para hepatite c
WO2003000203A3 (en) Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling
ATE308328T1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
EA200600603A1 (ru) Оральная система доставки лекарственного препарата
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
PA8549401A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido
AR042308A1 (es) Medicamento de administracion transdermica y transmucosica con absorcion mejorada de principios activos
AR003001A1 (es) Composicion farmaceutica estimuladora de la osteogenesis.
PT1406859E (pt) Derivados substituídos de 4-aminociclo-hexanol
BRPI0410967A (pt) compostos, composições e seus usos para o tratamento de infecções por vìrus da famìlia flaviviridae
EP1603595A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE
AR034767A1 (es) Combinacion de principios activos para la terapia medicinal de la dependencia a la nicotina.
SV2002000065A (es) Dosis mensuales para el tratamiento de las infecciones por streptococcus pneumoniae ref. x-12423
UA34406A (uk) Засіб для лікування розсіяного склерозу, спосіб лікування з його використанням та фармацевтична упаковка
IT202200006347A1 (it) Sistema di supporto per postazioni di trattamento di una persona.

Legal Events

Date Code Title Description
FB Suspension of granting procedure